Form 8-K - Current report:
SEC Accession No. 0001178913-25-000259
Filing Date
2025-01-30
Accepted
2025-01-30 09:26:29
Documents
17
Period of Report
2025-01-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2532621.htm   iXBRL 8-K 76718
2 EXHIBIT 10.1 exhibit_10-1.htm EX-10.1 62239
3 EXHIBIT 10.2 exhibit_10-2.htm EX-10.2 123358
4 EXHIBIT 10.3 exhibit_10-3.htm EX-10.3 126112
  Complete submission text file 0001178913-25-000259.txt   651341

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA slxn-20250129.xsd EX-101.SCH 4740
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20250129_def.xml EX-101.DEF 18263
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20250129_lab.xml EX-101.LAB 27748
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20250129_pre.xml EX-101.PRE 20505
20 EXTRACTED XBRL INSTANCE DOCUMENT zk2532621_htm.xml XML 6552
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42253 | Film No.: 25571386
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)